Six or eight cycles of CHOP plus rituximab for elderly patients with diffuse large B-cell lymphoma: Updated results of the RICOVER-60 trial

被引：0
|
作者：
Muneer, Sabeeha
Cunningham, Sonia
机构：
来源：
CLINICAL LYMPHOMA & MYELOMA | 2008年 / 8卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [1] Six cycles of CHOP given with rituximab is adequate for elderly patients with diffuse large B-cell lymphorna: Findings of the RICOVER-60 trial
    Reddy, GK
    CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (04): : 263 - 264
  • [2] Six, not eight cycles of bi-weekly CHOP with rituximab (RCHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL).
    Pfreundschuh, M
    Kloess, M
    Schmits, R
    Zeynalova, S
    Lengfelder, E
    Franke, A
    Steinhauer, H
    Reiser, M
    Clemens, M
    Nickenig, C
    de Wit, M
    Hoffmann, M
    Mertelsmann, R
    Metzner, B
    Ho, A
    Truemper, L
    Eimermacher, H
    Mergenthaler, H
    Liersch, R
    Duehrsen, U
    Balleisen, L
    Hartmann, F
    Poeschel, V
    Schmitz, N
    Loeffler, M
    BLOOD, 2005, 106 (11) : 9A - 9A
  • [3] Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the completed RICOVER-60 trial of the german high-grade non-Hodgkin lymphoma study group (DSHNHL).
    Pfreundschuh, Michael
    Kloess, Marita
    Zeynalova, Samira
    Lengfelder, Eva
    Franke, Astrid
    Reiser, Marcel
    Steinhauer, Hjalmar
    Clemens, Michael
    Nickenig, Christina
    de Wit, Maike
    Metzner, Bernd
    Hensel, Manfred
    Mergenthaler, Hans-Guenther
    Liersch, Ruediger
    Duehrsen, Ulrich
    Balleisen, Leopold
    Engelhardt, Monika
    Poeschel, Viola
    Schubert, Joerg
    Truemper, Lorenz
    Schmitz, Norbert
    Loeffler, Markus
    BLOOD, 2006, 108 (11) : 64A - 65A
  • [4] Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
    Pfreundschuh, Michael
    Schubert, Joerg
    Ziepert, Marita
    Schmits, Rudolf
    Mohren, Martin
    Lengfelder, Eva
    Reiser, Marcel
    Nickenig, Christina
    Clemens, Michael
    Peter, Norma
    Bokemeyer, Carsten
    Eimermacher, Hartmut
    Ho, Anthony
    Hoffmann, Martin
    Mertelsmann, Roland
    Truemper, Lorenz
    Balleisen, Leopold
    Liersch, Ruediger
    Metzner, Bernd
    Hartmann, Frank
    Glass, Bertram
    Poeschel, Viola
    Schmitz, Norbert
    Ruebe, Christian
    Feller, Alfred C.
    Loeffler, Markus
    LANCET ONCOLOGY, 2008, 9 (02): : 105 - 116
  • [5] Rituximab and CHOP for elderly patients with diffuse large B-cell lymphoma
    Carol S. Portlock
    Current Oncology Reports, 2003, 5 (5) : 357 - 357
  • [6] Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial
    Glass, B.
    Dohm, A. J.
    Truemper, L. H.
    Pfreundschuh, M.
    Bleckmann, A.
    Wulf, G. G.
    Rosenwald, A.
    Ziepert, M.
    Schmitz, N.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3058 - 3064
  • [7] CHOP chemotherapy plus rituximab compared with CHOP alone in diffuse large B-cell lymphoma patients
    Poddubnaya, I
    Osmanov, D
    Babicheva, L
    Falaleeva, N
    ANNALS OF ONCOLOGY, 2005, 16 : 177 - 177
  • [8] Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial.
    Coiffier, B
    Lepage, E
    Herbrecht, R
    Tilly, H
    Solal-Celigny, P
    Munck, JN
    Bouabdallah, R
    Lederlin, P
    Sebban, C
    Morel, P
    Haioun, C
    Salles, G
    Molina, T
    Gisselbrecht, C
    BLOOD, 2000, 96 (11) : 223A - 223A
  • [9] Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
    Kuhnl, A.
    Cunningham, D.
    Counsell, N.
    Hawkes, E. A.
    Qian, W.
    Smith, P.
    Chadwick, N.
    Lawrie, A.
    Mouncey, P.
    Jack, A.
    Pocock, C.
    Ardeshna, K. M.
    Radford, J.
    McMillan, A.
    Davies, J.
    Turner, D.
    Kruger, A.
    Johnson, P. W.
    Gambell, J.
    Rosenwald, A.
    Ott, G.
    Horn, H.
    Ziepert, M.
    Pfreundschuh, M.
    Linch, D.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1540 - 1546
  • [10] Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
    Ott, German
    Ziepert, Marita
    Klapper, Wolfram
    Horn, Heike
    Szczepanowski, Monika
    Bernd, Heinz-Wolfram
    Thorns, Christoph
    Feller, Alfred C.
    Lenze, Dido
    Hummel, Michael
    Stein, Harald
    Mueller-Hermelink, Hans-Konrad
    Frank, Matthias
    Hansmann, Martin-Leo
    Barth, Thomas F. E.
    Moeller, Peter
    Cogliatti, Sergio
    Pfreundschuh, Michael
    Schmitz, Norbert
    Truemper, Lorenz
    Loeffler, Markus
    Rosenwald, Andreas
    BLOOD, 2010, 116 (23) : 4916 - 4925
12345